Indoco Remedies

Indoco Remedies P/FCF

The P/FCF (Price-to-Free-Cash-Flow Ratio) of Indoco Remedies (INDOCO.NS) as of Oct 19, 2026 is -16.22. In the previous year, P/FCF (Price-to-Free-Cash-Flow Ratio) was -5.69 — a change of 185.20% (lower).

P/FCF

-16.22

YoY

185.20%

Last updated:

P/FCF (Price-to-Free-Cash-Flow Ratio) of Indoco Remedies is 2026 -16.22 . P/FCF (Price-to-Free-Cash-Flow Ratio) of Indoco Remedies was 2025 -5.69 . It decreases by 185.20% lower compared to the previous year.

The Indoco Remedies P/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/FCF
Date
P/FCF
Jan 1, 2019
53.08 INR
Jan 1, 2020
28.99 INR
Jan 1, 2021
347.40 INR
Jan 1, 2022
38.48 INR
Jan 1, 2023
-65.66 INR
Jan 1, 2024
-6.86 INR
Jan 1, 2025
-5.69 INR
Jan 1, 2026
-16.22 INR
The Indoco Remedies P/FCF history
YEARP/FCFYoY
-16.22+185.20%
-5.69-17.17%
-6.86-89.54%
-65.66-270.61%
38.48-88.92%
347.40+1,098.25%
28.99-45.38%
53.08-147.58%
-111.57+503.28%
-18.49-115.49%
119.37+32.78%
89.90+174.74%
32.72—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Indoco Remedies Stock analysis

What does Indoco Remedies do? Indoco Remedies Ltd, listed on the National Stock Exchange of India with ticker INDOCO.NS and ISIN INE873D01024, is a pharmaceutical company headquartered in Mumbai, India. The company operates within the Health Care sector, specifically in the Pharmaceuticals industry. It employs 6,101 full-time employees and went public via an IPO on January 7, 2005. Indoco Remedies Ltd focuses on the manufacturing and marketing of formulations, including finished dosage forms and active pharmaceutical ingredients (APIs). The company serves multiple therapeutic categories such as diabetology, respiratory care, stomatology, women's health, nutritional products, gastroenterology, cardiology, metabolic disorders, and primary care medicine. Its product portfolio includes brands like Cyclopam, Sensodent-K, Karvol Plus, Sensoform, Cital UTI, Kidodent, Rexidin M, Lignox A, Dentogel, Aloja, Homide, Renolen, Noxa, Dexoren - S, Aloja M, ATM, Febrex Plus, Sensodent-KF, SM Fibro, MCBM 69, Cal Aid, Snowdent, Dropizin, Zincoren, Coloferrin, Bfloren, RR Sensoform Dental, Mofloren-D, and Tuspel. The company caters to both domestic and international markets. Indoco Remedies Ltd has subsidiaries including Xtend Industrial Designers and Engineers Pvt Ltd, Indoco Remedies Czech sro, and Indoco Remedies UK Limited. The company's website is https://www.indoco.com/. Indoco Remedies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Indoco Remedies stock

P/FCF (Price-to-Free-Cash-Flow Ratio) of Indoco Remedies is -16.22 in 2026.

P/FCF (Price-to-Free-Cash-Flow Ratio) of Indoco Remedies changed from -5.69 to -16.22, representing a 185.20% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/FCF (Price-to-Free-Cash-Flow Ratio) Indoco Remedies since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Free-Cash-Flow ratio measures how much investors pay for each unit of free cash flow. A lower ratio may indicate better value.

P/FCF = Market Capitalization / Free Cash Flow

To evaluate P/FCF (Price-to-Free-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/FCF (Price-to-Free-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/FCF (Price-to-Free-Cash-Flow Ratio)'s Indoco Remedies with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Indoco Remedies

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Indoco Remedies